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BACKGROUND
The meningococcal group B vaccine 4CMenB is a new, recombinant protein-based vac-
cine that is licensed to protect against invasive group B meningococcal disease. How-
ever, its role in preventing transmission and, therefore, inducing population (herd) 
protection is uncertain.
METHODS
We used cluster randomization to assign, according to school, students in years 10 to 
12 (age, 15 to 18 years) in South Australia to receive 4CMenB vaccination either at base-
line (intervention) or at 12 months (control). The primary outcome was oropharyngeal 
carriage of disease-causing Neisseria meningitidis (group A, B, C, W, X, or Y) in students 
in years 10 and 11, as identified by polymerase-chain-reaction assays for PorA (encoding 
porin protein A) and N. meningitidis genogroups. Secondary outcomes included carriage 
prevalence and acquisition of all N. meningitidis and individual disease-causing geno-
groups. Risk factors for carriage were assessed at baseline.
RESULTS
A total of 237 schools participated. During April through June 2017, a total of 24,269 
students in years 10 and 11 and 10,220 students in year 12 were enrolled. At 12 months, 
there was no difference in the prevalence of carriage of disease-causing N. meningitidis 
between the vaccination group (2.55%; 326 of 12,746) and the control group (2.52%; 291 
of 11,523) (adjusted odds ratio, 1.02; 95% confidence interval [CI], 0.80 to 1.31; P = 0.85). 
There were no significant differences in the secondary carriage outcomes. At baseline, 
the risk factors for carriage of disease-causing N. meningitidis included later year of 
schooling (adjusted odds ratio for year 12 vs. year 10, 2.75; 95% CI, 2.03 to 3.73), current 
upper respiratory tract infection (adjusted odds ratio, 1.35; 95% CI, 1.12 to 1.63), ciga-
rette smoking (adjusted odds ratio, 1.91; 95% CI, 1.29 to 2.83), water-pipe smoking 
(adjusted odds ratio, 1.82; 95% CI, 1.30 to 2.54), attending pubs or clubs (adjusted odds 
ratio, 1.54; 95% CI, 1.28 to 1.86), and intimate kissing (adjusted odds ratio, 1.65; 95% 
CI, 1.33 to 2.05). No vaccine safety concerns were identified.
CONCLUSIONS
Among Australian adolescents, the 4CMenB vaccine had no discernible effect on the 
carriage of disease-causing meningococci, including group B. (Funded by GlaxoSmith-
Kline; ClinicalTrials.gov number, NCT03089086.)
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Invasive meningococcal disease, caused by Neisseria meningitidis, is an important cause of disease and death worldwide, owing to 
difficulties in early diagnosis, a rapid clinical 
progression, and a high case fatality rate.1,2 The 
most important meningococcal disease–associ-
ated capsular groups are A, B, C, W, X, and Y, 
with group B disease predominating in many 
high-income countries, including Australia.1 In-
fants and adolescents are especially affected by 
meningococcal disease, and many countries are 
considering the implementation of meningococ-
cal B vaccine programs.1 A program involving 
administration of the meningococcal B vaccine 
4CMenB (Bexsero, GlaxoSmithKline) in infants 
that was introduced in the United Kingdom in 
2015 has been shown to protect of infants and 
toddlers for at least 2 years, following a two-
dose priming schedule plus a booster at 1 year.3
Exposure to N. meningitidis is common in the 
general population, leading to asymptomatic 
pharyngeal carriage, which may be transient or 
long term.4 Age influences carriage, with an in-
crease in carriage prevalence from 15 years of 
age to a peak at approximately 19 years, proba-
bly owing to increases in the numbers and close-
ness of social contacts and behavior.5-7 Meningo-
coccal disease is a rare outcome of infection, 
and the relationship between carriage and risk 
of disease is incompletely understood.8 Given 
that carriage and transmission rates are higher 
among adolescents than in other age groups, a 
reduction in carriage prevalence among adoles-
cents could provide indirect protection to unvac-
cinated persons, including infants.6
Conjugate polysaccharide vaccines can induce 
mucosal respiratory responses that interfere with 
acquisition of carriage of several meningococcal 
capsular groups (e.g., group C and group W).9,10 
However, the same cannot be assumed for the 
protein and outer membrane vesicle antigens in 
meningococcal B vaccines, which, unlike capsu-
lar polysaccharides, vary antigenically among the 
circulating strains that express them. The South 
Australian meningococcal B vaccine carriage study 
“B Part of It” examined the effect of 4CMenB, a 
multiantigen vaccine designed to control group B 
meningococcal disease, on the carriage of disease-
causing meningococci in adolescent students in 
order to inform the design of meningococcal 
vaccine programs and the assessment of cost-
effectiveness globally.11,12
Me thods
Trial Design and Oversight
This investigator-initiated and -led, parallel, 
cluster-randomized, controlled trial was conduct-
ed in the Australian state of South Australia 
from 2017 through 2018 in accordance with a 
previously published protocol,12 available with 
the full text of this article at NEJM.org. The trial 
was designed and overseen by an independent 
scientific advisory committee and was managed 
by the University of Adelaide. GlaxoSmithKline 
provided a research grant to fund the trial and 
provided 4CMenB vaccine free of charge. Employ-
ees of GlaxoSmithKline contributed to the trial 
conception, the protocol, and the interpretation 
of results but played no role in the data collec-
tion or analysis.
The protocol was approved by the Women’s 
and Children’s Health Network Human Research 
Ethics Committee.12 The trial was performed in 
accordance with the Declaration of Helsinki and 
with the Good Clinical Practice guidelines of the 
International Council for Harmonisation of Tech-
nical Requirements for Pharmaceuticals for Hu-
man Use. The authors assume responsibility for 
the accuracy and completeness of the data and 
vouch for the fidelity of the trial to the protocol.
Participants
All 260 secondary schools in South Australia 
were invited to participate, with oropharyngeal 
swabbing and vaccination of students provided 
through the school immunization program, 
which was managed by the Immunisation Sec-
tion of SA Health. Each school year level in 
South Australia comprises 19,000 to 20,000 
students. All secondary school students in years 
10, 11, and 12 (approximately 15 to 18 years of 
age) in 2017 were eligible to participate if they 
provided written informed consent (for those 
≥18 years of age or older; those <18 years of age 
provided assent, with written informed consent 
obtained from a parent or guardian), were avail-
able at school to undergo at least the first oro-
pharyngeal swabbing, and were willing to adhere 
to the trial procedures. Students were ineligible 
if they had received 4CMenB previously, had 
previously had an anaphylactic reaction to any 
component of the vaccine, or were known to be 
pregnant.
Because year 12 is the final year of schooling 
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in Australia, the trial was designed to include 
the 12-month results of oropharyngeal swabbing 
only in students who were in years 10 and 11 in 
the first year of the study in order to provide 
data for the primary-outcome analysis. Students 
in year 12 contributed to the baseline analysis of 
risk factors for carriage because they were likely 
to have the highest carriage rates and also in an 
effort to reduce any possible effect of the vaccine 
on carriage due to the mixing of unimmunized 
year 12 students with immunized year 10 and 11 
students at schools assigned to the vaccination 
group.
Outcomes
The primary outcome was the prevalence of 
carriage of any disease-causing genogroup of 
N. meningitidis (A, B, C, W, X, or Y) at 12 months. 
Secondary outcomes were the prevalence of car-
riage at 12 months of each individual genogroup 
(A, B, C, W, X, and Y) and of any N. meningitidis 
and the acquisition of carriage (i.e., negative sta-
tus at baseline and positive status at 12 months) 
of disease-causing genogroups and of any 
N. meningitidis. In addition to comparisons of 
the randomized groups, a further objective of the 
trial was to identify the characteristics associ-
ated with baseline carriage of disease-causing 
genogroups and any N. meningitidis.
Randomization and Blinding
Schools were randomly assigned to the interven-
tion group (in which students received two 
doses of 4CMenB 2 months apart) or the control 
group (in which students received 4CMenB vac-
cination after the 12-month oropharyngeal swab). 
Stratification factors were school size (<60, 60 to 
119, and ≥120 students per year level) and 
school socioeconomic status, as measured by the 
Index of Community Socio-Educational Advan-
tage (ICSEA; scores range from approximately 
500 to 1300, with higher scores indicating more 
educational advantage; the categories for this 
study were as follows: <970 [low], 970 to 1020 
[medium], and >1020 [high]).13 The randomiza-
tion schedule was generated by an independent 
statistician using Stata software, version 14. School 
staff and students were unaware of their group 
assignments until the day of the first trial visit 
(Fig. S1 in the Supplementary Appendix, avail-
able at NEJM.org). Laboratory personnel and in-
vestigators were unaware of the group assign-
ments for the duration of the trial.
Trial Processes
Written informed consent was obtained from a 
parent or guardian with assent obtained from 
the student (for those <18 years of age), or writ-
ten informed consent was obtained from the 
student (for those ≥18 years of age). Participants 
completed a questionnaire to obtain information 
on characteristics relevant to meningococcal car-
riage (e.g., smoking history, household size, and 
recent antibiotic use) at each swab visit at school 
and were provided with an A$20 iTunes gift card 
on questionnaire completion. All the collected 
data were securely stored in a database held by 
Adelaide Health Technology Assessment at the 
University of Adelaide.
Oropharyngeal swabs were obtained by nurses 
using a standardized technique of wiping a floc-
culated swab across the posterior oropharynx 
from one tonsillar area to the other. Swabs were 
placed immediately in a transport medium (skim 
milk, tryptone, glucose, and glycerine; Thermo 
Fisher Scientific), placed in a portable cooler, 
and delivered to a central laboratory (SA Pathol-
ogy). On receipt of the samples, DNA was ex-
tracted with the use of Roche MagNA Pure ana-
lyzers, followed by polymerase-chain-reaction 
(PCR) screening for the presence of specific 
meningococcal DNA. An assay specific for the 
detection of PorA (encoding porin protein A) was 
used because of its high sensitivity to and speci-
ficity for all pharyngeal carriage of N. meningiti-
dis.14,15 Samples with a positive result for PorA on 
PCR were genogrouped according to group-spe-
cific PCR results (genogroups A, B, C, W, X, and Y) 
and subsequently cultured for neisseria species 
on selective agar with incubation in 5% carbon 
dioxide at 35°C. Plates were examined daily up to 
72 hours for the presence of N. meningitidis. All 
isolates were identified by means of standard 
diagnostic laboratory methods, including oxidase 
reaction, matrix-assisted laser desorption–ioniza-
tion with time-of-flight mass spectrometry, and 
a further genogrouping PCR assay.12 Samples 
and isolates were classified as not able to be 
grouped if the capsule biosynthesis genes for 
these genogroups were not detected.
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Statistical Analysis
Assuming a carriage prevalence of 8% in the 
unvaccinated cohort,16 we calculated that a sam-
ple of 12,160 participants in each group would 
provide the trial with 90% power to detect a 20% 
relative lower risk of carriage (6.4% vs. 8%) 
among vaccinated participants (at a two-tailed 
alpha of 0.05). If enrollment or trial completion 
were lower than expected, the trial would still 
have 80% power, provided that swab results at 
12 months were obtained for at least 8970 par-
ticipants per group. These calculations incorpo-
rated a design effect of 2.19, on the basis of an 
average of 120 students per school and an intra-
class correlation coefficient estimate of 0.01.17
Analyses were undertaken according to a pre-
specified statistical analysis plan. Data were 
analyzed according to the randomized group of 
the student’s school (intention-to-treat principle). 
A sensitivity per-protocol analysis of the primary 
outcome was also conducted; this analysis in-
cluded students in the vaccination group who 
received two doses of 4CMenB and students in 
the control group who did not receive 4CMenB 
before the 12-month follow-up.
The primary outcome of carriage of disease-
causing N. meningitidis genogroups detected by 
PCR at 12 months was compared between groups 
with the use of logistic regression, with general-
ized estimating equations used to account for 
clustering at the school level. The difference in 
carriage between groups was expressed as an 
odds ratio with a 95% confidence interval. Ad-
justment was made for the student’s baseline 
carriage and randomization strata (school size 
and ICSEA category). Secondary carriage out-
comes were also compared between groups with 
the use of logistic generalized estimating equa-
tions. Missing data on the carriage outcomes 
were addressed with the use of multiple imputa-
tion, with imputation performed separately for 
the two randomized groups with the use of 
chained equations.18 In planned subgroup analy-
ses of the primary and secondary outcomes, the 
effect of the 4CMenB vaccine was examined 
separately in metropolitan and rural schools and 
in students in year 10 and year 11; on the basis 
of the number of interaction tests, one signifi-
cant test (P<0.05) would be expected by chance 
alone. No adjustment was made for multiple 
hypothesis testing, so P values are provided only 
for the primary outcome and for interaction 
tests in subgroup analyses. All the analyses were 
performed with the use of SAS software, version 
9.4, and Stata software, version 15.
R esult s
Characteristics of the Participants
A total of 34,489 students in year 10, 11, or 12 
were enrolled between April 1 and June 30, 2017, 
from 237 participating schools. A total of 24,269 
students in years 10 and 11 (12,746 students in 
the vaccination group and 11,523 in the control 
group) contributed data for the primary-outcome 
analysis (Fig. 1). A total of 10,220 students in 
year 12 contributed to the analysis of risk factors 
for carriage. Primary-outcome data were avail-
able for 21,126 students (87.0%) after the with-
drawal of 43 students and loss to follow-up of 
3100 students (Fig. 1).
The characteristics of the participants at base-
line were similar in the two groups (Table 1). In 
the vaccination group, 99.9% of the students 
received the first dose of 4CMenB, and 97.7% 
received the second dose.
Primary Outcome
There was no significant difference in carriage 
prevalence of disease-causing N. meningitidis be-
tween the vaccination group (326 of 12,746 stu-
dents [2.55%]) and the control group (291 of 
11,523 students [2.52%]) in the intention-to-treat 
analysis at 12 months (difference, 0.03 percent-
age points; adjusted odds ratio, 1.02; 95% con-
fidence interval [CI], 0.80 to 1.31; P = 0.85) 
(Table 2). The adjusted intraclass correlation 
coefficient for the primary outcome was 0.005. 
There was little evidence of an effect of treat-
ment when the analysis was restricted to com-
plete cases, under a per-protocol or post hoc 
Bayesian analysis, or in sensitivity analyses that 
used the missing-data mechanism (see the Sup-
plementary Appendix).
Secondary Outcomes
There were no significant between-group differ-
ences in any of the prespecified secondary out-
comes regarding carriage (Table 2). In a post 
hoc analysis, the risk of nongroupable N. menin-
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gitidis was 29% lower in the vaccination group 
than in the control group (1.65% vs. 2.23%; ad-
justed odds ratio, 0.71; 95% CI, 0.54 to 0.91). 
Unimputed results were similar for all outcomes 
(Table S4).
Risk Factors for Carriage
The risk factors for carriage of disease-causing 
N. meningitidis for all students enrolled in year 10, 
11, or 12 included the following: later year of 
schooling (adjusted odds ratio for year 12 vs. 
year 10, 2.75; 95% CI, 2.03 to 3.73), current up-
per respiratory tract infection (adjusted odds ra-
tio, 1.35; 95% CI, 1.12 to 1.63), cigarette smok-
ing in the past week (adjusted odds ratio, 1.91; 
95% CI, 1.29 to 2.83), water-pipe smoking in the 
past week (adjusted odds ratio, 1.82; 95% CI, 
1.30 to 2.54), attending pubs or clubs in the past 
week (adjusted odds ratio, 1.54; 95% CI, 1.28 to 
1.86), participation in intimate kissing in the 
past week (adjusted odds ratio, 1.65; 95% CI, 
1.33 to 2.05), and being white (adjusted odds 
ratio for Asian vs. white race, 0.50; 95% CI, 0.31 
to 0.80) (Table 3). The risk factors associated 
with carriage prevalence of any meningococci 
were similar, with the additional results that 
students of Aboriginal or Torres Strait Islander 
ethnicity had almost double the carriage preva-
lence as that among white students (6.72% vs. 
3.66%; adjusted odds ratio, 1.49; 95% CI, 1.07 to 
Figure 1. Consent, Randomization, and Follow-up of the Participants.
Written informed consent was obtained from a parent or guardian with assent obtained from the student (for those 
<18 years of age), or written informed consent was obtained from the student (for those ≥18 years of age).
26,156 Underwent randomization
according to school
26,156 Students in yr 10 or 11
provided consent or assent
13,687 Were assigned to vaccination group 12,469 Were assigned to control group
946 Were ineligible
924 Did not attend first
visit
11 Were ineligible according to
checklist review
11 Declined to undergo
baseline swabbing
941 Were ineligible
912 Did not attend first
visit
18 Were ineligible according to
checklist review
11 Declined to undergo
baseline swabbing
12,746 Were included in the analysis
of the primary outcome
11,523 Were included in the analysis
of the primary outcome
12,746 Entered trial 11,523 Entered trial
16 Did not receive vaccine
19 Withdrew
17 Were withdrawn by self
or parent
2 Had medical reason
1 Received vaccine
24 Withdrew
23 Were withdrawn by self
or parent
1 Had medical reason
10,841 Underwent swabbing in 2018 10,285 Underwent swabbing in 2018
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2.06) and boarding students were at higher risk 
than day students (adjusted odds ratio, 2.10; 
95% CI, 1.16 to 3.80) (Table S3).
Overall vaccine coverage (percentage of stu-
dents who received the vaccine) among South 
Australian students was 62% (students in years 
10 and 11 enrolled in the trial, divided by the 
total number of students in years 10 and 11). 
Vaccine coverage was at least 50% in 82% of the 
participating schools (89 of 109 schools) that 
Characteristic
Vaccination Group 
 (N = 12,746)
Control Group 
(N = 11,523)
School ICSEA category — no. (%)†
<970 2175 (17.06) 2471 (21.44)
970 to 1020 3763 (29.52) 3601 (31.25)
>1020 6808 (53.41) 5451 (47.31)
School size — no. (%)‡
<60 students/year level 2112 (16.57) 1536 (13.33)
60 to 119 students/year level 4181 (32.80) 3903 (33.87)
>119 students/year level 6453 (50.63) 6084 (52.80)
School location — no. (%)
Metropolitan 9829 (77.11) 8147 (70.70)
Rural 2917 (22.89) 3376 (29.30)
Year of schooling — no. (%)
10 6576 (51.59) 6188 (53.70)
11 6170 (48.41) 5335 (46.30)
Age — yr 15.6±0.7 15.6±1.2
Female sex — no. (%) 6670 (52.33) 5795 (50.29)
Boarding student — no./total no. (%) 340/12,686 (2.68) 190/11,469 (1.66)
Smoking in previous week — no./total no. (%)
Cigarettes 209/12,666 (1.65) 181/11,454 (1.58)
Electronic cigarette 127/12,626 (1.01) 127/11,408 (1.11)
Water pipe 369/12,626 (2.92) 281/11,406 (2.46)
N. meningitidis carriage — no./total no. (%)
Disease­causing genogroup§ 169/12,735 (1.33) 163/11,519 (1.42)
Any N. meningitidis 356/12,735 (2.80) 302/11,519 (2.62)
Genogroup B 106/12,735 (0.83) 83/11,519 (0.72)
Genogroup C 3/12,735 (0.02) 7/11,519 (0.06)
Genogroup W 9/12,735 (0.07) 11/11,519 (0.10)
Genogroup X 2/12,735 (0.02) 2/11,519 (0.02)
Genogroup Y 52/12,735 (0.41) 63/11,519 (0.55)
*  Plus–minus values are means ±SD. There was no significant difference in the baseline characteristics between the 
groups after clustering at the school level was accounted for. Percentages may not total 100 because of rounding.
†  Scores on the Index of Community Socio­Educational Advantage (ICSEA) range from approximately 500 to 1300, with 
higher scores indicating more educational advantage. A score between 970 and 1020 indicates average status and is 
considered a benchmark.13 The categories for this study were as follows: less than 970 (low), 970 to 1020 (medium), 
and greater than 1020 (high). The scores for all schools involved in the study ranged from 515 to 1177, with a median 
score of 1000.
‡  School size was assessed as follows: fewer than 60 students per year level indicated small size, 60 to 119 students per 
year level indicated medium size, and more than 119 students per year level indicated large size.
§  Disease­causing genogroup refers to all capsular genogroups identified (B, C, W, X, and Y).
Table 1. Baseline Characteristics of the Students in Years 10 and 11, According to Trial Group.*
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had been randomly assigned to the vaccination 
group. There was no association between vac-
cine coverage and outcomes in schools in the 
vaccination group regarding carriage of disease-
causing N. meningitidis (odds ratio per 1-percent-
age-point increase in coverage, 1.01; 95% CI, 
0.995 to 1.02) or any N. meningitidis (odds ratio, 
1.00; 95% CI, 0.99 to 1.01).
Subgroup Analyses According to 
Randomization Strata
Primary and secondary outcomes stratified ac-
cording to school location (metropolitan or ru-
ral) and school year level (year 10 or 11) pro-
vided evidence of effect modification according 
to school location for the carriage of disease-
causing meningococcal disease genogroups and 
all genogroups and for the acquisition of disease-
causing genogroups (Tables S4 and S5). Post hoc 
tests revealed increased carriage (adjusted odds 
ratio, 1.49; 95% CI, 1.03 to 2.15) and acquisition 
(adjusted odds ratio, 1.50; 95% CI, 1.03 to 2.18) 
of disease-causing genogroups in rural schools 
and decreased overall carriage in metropolitan 
schools (adjusted odds ratio, 0.73; 95% CI, 0.58 
to 0.93) in the vaccination group. However, these 
results should be interpreted with caution given 
the large numbers of interaction tests. There was 
no evidence of effect modification according to 
year level.
Disease Effect and Safety
There were no cases of meningococcal B disease 
in this trial population during the trial period 
(2017–2018) and no cases to date (as of Decem-
ber 27, 2019), as compared with 12 cases among 
students 15 to 18 years of age from the period 
2015–2016.19 After immunization, 193 adverse 
events were reported (in 187 of 58,639 students 
[0.32%]), of which 9 were serious adverse events 
(Table S7). The most common adverse events were 
injection-site reactions (in 126 students), head-
ache (in 99), and nausea (in 61).
Discussion
This cluster-randomized, controlled trial provided 
evidence that 4CMenB had no effect on the car-
riage of disease-causing meningococci (includ-
ing group B) in adolescents. These results have 
Outcome
Vaccination Group 
(N = 12,746)
Control Group 
(N = 11,523)
Odds Ratio 
(95% CI)†
no. (%)
Carriage of disease­causing genogroup 326 (2.55) 291 (2.52) 1.02 (0.80–1.31)‡
Carriage of any N. meningitidis 547 (4.29) 561 (4.87) 0.85 (0.70–1.04)
Carriage of genogroup B 164 (1.29) 135 (1.18) 1.10 (0.81–1.47)
Carriage of genogroup Y 117 (0.92) 131 (1.13) 0.81 (0.56–1.18)
Carriage of genogroup W§ 17 (0.16) 18 (0.18) 0.89 (0.43–1.85)
Carriage of genogroup C§ 12 (0.11) 7 (0.07) 1.87 (0.63–5.55)
Carriage of genogroup X§ 8 (0.07) 1 (0.01) 7.59 (0.98–58.83)¶
Acquisition of any N. meningitidis 430 (3.38) 427 (3.70) 0.91 (0.73–1.13)
Acquisition of disease­causing genogroup 272 (2.13) 238 (2.07) 1.03 (0.79–1.34)
*  A P value is provided for the primary outcome only. The 95% confidence intervals for secondary outcomes have not 
been adjusted for multiple comparisons and hence should not be used to imply treatment effects. Missing data were 
multiply imputed. Average numerators across the 100 imputed data sets were rounded to the nearest integer value and 
hence may not correspond exactly with reported percentages. Genogroup A was not detected in any student.
†  Analysis was adjusted for randomization strata and (excluding acquisition outcomes) corresponding baseline carriage 
result.
‡  P = 0.85.
§  Multiple imputation was not applied owing to the small numbers of cases. Complete data were available for 10,841 
 students in the vaccination group and for 10,285 in the control group.
¶  We did not perform an adjusted analysis owing to the small number of cases.
Table 2. Analysis of Primary and Secondary Outcomes for N. meningitidis Carriage and Acquisition at 12 Months  
with the Use of Multiple Imputation.*
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informed policies regarding control of meningo-
coccal disease, assessments of cost-effectiveness 
of 4CMenB immunization programs globally, 
and the design of the next generation of menin-
gococcal B vaccines. Our findings differ from 
those regarding group A and C polysaccharide 
conjugate vaccines, in which an effect on carriage 
rates has been seen in observational studies as-
sessing the effect of population-based vaccina-
tion programs.9,20-22 Conjugate vaccine programs 
that achieve high coverage in adolescents have 
provided evidence of indirect protection to other 
age groups, thus reducing the need for vaccina-
tion of infants.23,24
The lack of effect of 4CMenB on carriage of 
disease-causing meningococci emphasizes the 
Characteristic Participants Odds Ratio (95% CI)*
no./total no. (%)
Sex
Female 338/17,909 (1.89) 1.00
Male 330/16,550 (1.99) 1.09 (0.92–1.29)
Year of schooling
10 130/12,757 (1.02) 1.00
11 202/11,497 (1.76) 1.64 (1.20–2.23)
12 336/10,205 (3.29) 2.75 (2.03–3.73)
Current upper respiratory tract infection
No 478/26,959 (1.77) 1.00
Yes 186/7213 (2.58) 1.35 (1.12–1.63)
Smoked cigarettes in past week
No 615/33,630 (1.83) 1.00
Yes 49/628 (7.80) 1.91 (1.29–2.83)
Smoked water pipe in previous week
No 600/33,085 (1.81) 1.00
Yes 63/1042 (6.05) 1.82 (1.30–2.54)
Days out at pub or club in past week
0 421/27,226 (1.55) 1.00
≥1 246/7064 (3.48) 1.54 (1.28–1.86)
No. of persons kissed intimately in past week
0 372/25,865 (1.44) 1.00
≥1 278/7749 (3.59) 1.65 (1.33–2.05)
Boarding student
No 644/33,546 (1.92) 1.00
Yes 21/756 (2.78) 1.33 (0.72–2.43)
Race or ethnic group†
White 506/24,686 (2.05) 1.00
Aboriginal or Torres Strait Islander 32/953 (3.36) 1.34 (0.90–2.01)
Asian 31/3383 (0.92) 0.50 (0.31–0.80)
Other 87/4936 (1.76) 0.98 (0.76–1.26)
*  Analyses were adjusted for the characteristics listed in the table as well as for school ICSEA category, school size, 
school location, antibiotic use, electronic cigarette use, and current relationship status.
†  Race and ethnic group were reported by participating students.
Table 3. Risk Factors for Carriage of Disease-Causing Genogroup at Baseline in Students in Year 10, 11, or 12.
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need for direct protection of those at highest 
risk for meningococcal disease. Because the in-
cidence of meningococcal disease peaks among 
preschool children and adolescents, it is impor-
tant to consider vaccination for direct protection 
in these age groups. In South Australia, where 
4CMenB is estimated to cover 90% of disease-
causing isolates,25 a program was implemented 
as of October 1, 2018, to vaccinate those at high-
est risk, including infants, toddlers (1 to 3 years 
of age), and adolescents and young adults (15 to 
20 years of age).26 It will be important to moni-
tor the effect of the vaccine in this population-
based program.
Our findings are consistent with those of a 
previous study, in which a small reduction in 
carriage of strains expressing groups C, W, or Y 
was attributed mostly to a reduction in group Y 
carriage with no effect on group B carriage.27 
The observed reduction in non–disease-causing 
meningococci in our trial may reflect an effect 
on unencapsulated meningococci, in which vac-
cine-type outer membrane proteins are poten-
tially more exposed. Whole-genome sequencing 
and Bexsero Antigen Sequence Typing analysis 
of all isolates may assist in determining predic-
tive coverage.
Smaller observational studies assessing the 
effect of 4CMenB and MenB-FHbp (Trumenba, 
Pfizer) in university outbreaks in the United 
States have also shown no significant effect on 
carriage.28,29 Combined with our findings, these 
observations have implications for outbreak-
control protocols. Although 4CMenB may reduce 
the risk of late cases in such outbreaks, it is 
unlikely to reduce transmission; therefore, anti-
biotics remain necessary to offer rapid elimina-
tion of carriage. Preexposure vaccination for 
those entering settings where the risk of out-
breaks is high is likely to be a more effective use 
of the vaccine.
Important aspects of the trial design include 
randomization at the school level; a real-world 
setting, because students were enrolled at an age 
at which meningococcal vaccine programs are 
introduced to prevent invasive disease; a short 
enrollment period; the high retention of students 
in the trial; and high adherence to the trial pro-
tocol.
A limitation of the trial was the lower-than-
anticipated prevalence of carriage of disease-
causing N. meningitidis among adolescents at 12 
months. Despite this, the 95% confidence inter-
val for the primary outcome in the intention-to-
treat analysis did not contain odds ratios less 
than 0.80, the value approximating our smallest 
clinically important difference. Similarly, per-
protocol and post hoc Bayesian sensitivity analy-
ses of the primary outcome provided little sup-
port for a clinically important effect of 4CMenB 
on carriage (Table S6), although the lower bound-
ary of the 95% confidence interval in the per-
protocol analysis was marginally less than 0.80. 
These results, along with the negative findings 
on secondary outcomes regarding carriage, sug-
gest that 4CMenB was ineffective in reducing 
carriage of disease-causing N. meningitidis.
The trial was also limited by the fact that we 
used a single outcome measure of carriage after 
vaccination at 12 months, but this was chosen to 
reduce seasonal variation and to ensure that any 
reduction in carriage was sustained at least until 
1 year after vaccination. Underestimation of the 
effect of vaccine on disease-causing or all menin-
gococci due to moderate coverage rates is pos-
sible, and unvaccinated students may serve as a 
source of ongoing transmission. However, vac-
cine coverage of approximately 65% is realistic 
for vaccine programs involving students in high 
schools, and there was no association between 
school-level coverage and carriage.
In conclusion, our results did not show an 
effect of 4CMenB on carriage of disease-causing 
meningococci in a program involving adolescents 
that had moderate-to-high vaccine coverage.
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